Posted 2/28/2024, 12:02:00 PM
Ginkgo Bioworks Bolsters AI-Driven Drug Discovery With Reverie Labs Acquisition
- Ginkgo Bioworks acquires assets of Reverie Labs, including AI/ML infrastructure and 4 key team members, to strengthen AI-driven drug discovery capabilities
- Aims to integrate Reverie's models and software to advance AI/ML experimental design and generative AI for small molecule programs
- Builds on Ginkgo's existing partnerships with companies like Merck, Pfizer, and Boehringer Ingelheim
- Acquisition to help create biological and chemical foundation models and validate discoveries
- Reverie's co-founders excited about technology's impact on solving biology problems on Ginkgo's platform